Moderna (MRNA) Chief Commercial Officer files baseline Form 3 insider statement

Rhea-AI Filing Summary

Moderna, Inc. filed a Form 3 for Banque Soria Ester, who serves as Chief Commercial Officer. This is an initial statement of beneficial ownership that establishes her status as a reporting insider. The filing does not list any stock or option transactions, so it functions mainly as a baseline disclosure of her role under insider reporting rules.

Key Terms

Form 3, Chief Commercial Officer, reporting person

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Chief Commercial Officer financial

""officer_title": "Chief Commercial Officer""

A chief commercial officer (CCO) is the senior executive responsible for a company’s revenue-generating activities, including sales, marketing, pricing, customer relationships and business development. Think of the CCO as the head coach who builds the game plan to win customers and grow sales; their effectiveness affects how fast a company earns money, enters new markets and sustains profits, making the role a key signal for investors about future revenue and competitive strength.

reporting person regulatory

""reportingPersons": [ { "name": "Banque Soria Ester""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 06/30/2026 - 04:34 PM Accepted by SEC EDGAR 06/30/2026 - 04:33 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Banque Soria Ester

(Last) (First) (Middle)

C/O MODERNA, INC.

325 BINNEY STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/15/2026

3. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [ MRNA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

The reporting person was appointed as Chief Commercial Officer, effective June 15, 2026. This Form 3 is being filed following the issuance of EDGAR filer credentials to the reporting person on June 29, 2026; application for such credentials was submitted promptly following the appointment, and the filing was made as soon as practicable after credentials were obtained.

No securities are beneficially owned.

	/s/ James Dillon, as Attorney-in-Fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Moderna (MRNA) Form 3 for Banque Soria Ester show?

The Form 3 for Banque Soria Ester at Moderna is an initial insider ownership statement. It identifies her as Chief Commercial Officer and a reporting person, but does not report any stock purchases, sales, or option exercises in this filing.

Did Banque Soria Ester buy or sell Moderna (MRNA) shares in this Form 3?

No, this Form 3 does not report any share purchases or sales by Banque Soria Ester. It simply establishes her as an insider at Moderna and provides a baseline disclosure required by SEC rules for new reporting persons.

Why is Banque Soria Ester considered an insider at Moderna (MRNA)?

Banque Soria Ester is treated as an insider because she is Moderna’s Chief Commercial Officer. Executive officers are subject to SEC reporting requirements, including filing Form 3 as an initial statement of beneficial ownership when they become reporting persons.

Does this Moderna (MRNA) Form 3 indicate any derivative positions or options?

No, the Form 3 summary shows no derivative transactions or remaining derivative positions for Banque Soria Ester. The derivative section is empty, indicating the filing does not disclose options or similar instruments in this particular report.

How many Moderna (MRNA) transactions are covered in Banque Soria Ester’s Form 3?

Banque Soria Ester’s Form 3 reflects no transactions in Moderna securities. The transaction summary lists zero buys, zero sells, and zero exercises, underscoring that this is a baseline ownership and status filing rather than a trade report.